<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="216039">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00272844</url>
  </required_header>
  <id_info>
    <org_study_id>03-11-189R</org_study_id>
    <nct_id>NCT00272844</nct_id>
  </id_info>
  <brief_title>Treatment of the Cholesterol Defect in Smith-Lemli-Opitz Syndrome</brief_title>
  <official_title>Treatment of the Cholesterol Defect in Smith-Lemli-Opitz Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children’s Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Children’s Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether supplementation with an oil-based
      cholesterol suspension will correct the biochemical abnormalities in cholesterol and its
      precursors in individuals with the Smith-Lemli-Opitz syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study involves treating individuals with the Smith-Lemli-Opitz syndrome, a rare inborn
      error of cholesterol metabolism, with supplemental cholesterol to determine it effects on
      biochemical sterol metabolites, growth, neuropsychological development, ophthalmologic and
      auditory function, ERG (electroretinogram) parameters, and CNS metabolites as determined by
      brain MRS-imaging. Safety of the supplemental cholesterol suspension is monitored by tests
      of hematologic, renal, and liver function at periodic intervals. There is also a substudy
      that is investigating potential genotype-phenotype correlations, as well as another that
      studies biochemical parameters of light sensitivity in cultured skin fibroblasts from
      affected patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1998</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in sterol levels monitored q.3-6 months</measure>
    <time_frame>q. 3-6 months over 20+ years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improved general health, growth, and behavior</measure>
    <time_frame>q. 3-6 months over 20 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improved neuropsychological development</measure>
    <time_frame>q. 3-6 months over 20+ years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Smith-Lemli-Opitz Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>crystalline cholesterol oil-based suspension</intervention_name>
    <description>200 mg/mL suspension of crystalline cholesterol in oil. Dosage (generally 75-300 mg/kg/day in divided doses) is based on initial cholesterol levels and regulated to increase, yet maintain, cholesterol levels no higher than normal ranges.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biochemical confirmation of sterol defect associated with Smith-Lemli-Opitz syndrome

        Exclusion Criteria:

          -  Inability to tolerate crystalline cholesterol

          -  Inability to travel to Boston 3-4 times/year based on age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mira Irons, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children’s Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Irons M, Elias ER, Tint GS, Salen G, Frieden R, Buie TM, Ampola M. Abnormal cholesterol metabolism in the Smith-Lemli-Opitz syndrome: report of clinical and biochemical findings in four patients and treatment in one patient. Am J Med Genet. 1994 May 1;50(4):347-52.</citation>
    <PMID>8209913</PMID>
  </results_reference>
  <results_reference>
    <citation>Elias ER, Irons MB, Hurley AD, Tint GS, Salen G. Clinical effects of cholesterol supplementation in six patients with the Smith-Lemli-Opitz syndrome (SLOS). Am J Med Genet. 1997 Jan 31;68(3):305-10.</citation>
    <PMID>9024564</PMID>
  </results_reference>
  <results_reference>
    <citation>Irons M, Elias ER, Abuelo D, Bull MJ, Greene CL, Johnson VP, Keppen L, Schanen C, Tint GS, Salen G. Treatment of Smith-Lemli-Opitz syndrome: results of a multicenter trial. Am J Med Genet. 1997 Jan 31;68(3):311-4.</citation>
    <PMID>9024565</PMID>
  </results_reference>
  <results_reference>
    <citation>Caruso PA, Poussaint TY, Tzika AA, Zurakowski D, Astrakas LG, Elias ER, Bay C, Irons MB. MRI and 1H MRS findings in Smith-Lemli-Opitz syndrome. Neuroradiology. 2004 Jan;46(1):3-14. Epub 2003 Nov 5.</citation>
    <PMID>14605787</PMID>
  </results_reference>
  <results_reference>
    <citation>Elias ER, Hansen RM, Irons M, Quinn NB, Fulton AB. Rod photoreceptor responses in children with Smith-Lemli-Opitz syndrome. Arch Ophthalmol. 2003 Dec;121(12):1738-43.</citation>
    <PMID>14662594</PMID>
  </results_reference>
  <verification_date>July 2011</verification_date>
  <lastchanged_date>July 13, 2011</lastchanged_date>
  <firstreceived_date>January 4, 2006</firstreceived_date>
  <responsible_party>
    <name_title>Mira Irons M.D.</name_title>
    <organization>Children's Hospital Boston</organization>
  </responsible_party>
  <keyword>cholesterol</keyword>
  <keyword>Smith-Lemli-Opitz syndrome</keyword>
  <keyword>mental retardation</keyword>
  <keyword>sterols</keyword>
  <keyword>congenital anomalies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Cleft Palate</mesh_term>
    <mesh_term>Hypertelorism</mesh_term>
    <mesh_term>Hypospadias</mesh_term>
    <mesh_term>Genetic Diseases, X-Linked</mesh_term>
    <mesh_term>Smith-Lemli-Opitz Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
